Imago BioSciences, Inc. (IMGO)
| Market Cap | 516.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.70M |
| Shares Out | 32.20M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 27 |
| Last Price | $16.05 |
| Previous Close | $16.00 |
| Change ($) | 0.05 |
| Change (%) | 0.31% |
| Day's Open | 15.75 |
| Day's Range | 15.24 - 16.57 |
| Day's Volume | 41,926 |
| 52-Week Range | 14.99 - 17.95 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ImagoBioSciences--Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #IMGO--Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock
Imago BioSciences, Inc. has filed to go public with an IPO on the NASDAQ.
About IMGO
Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing internally-discovered novel inhibitors and degraders of LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow, to improve the quality of life of patients with cancer and bone marrow diseases, in addition to prolonging their lives. Our lead product candidate is bomedemstat for the treatment of certain myeloproliferative neoplasms, or MPNs, a family of related, chronic cancers of the bone marrow. The three most common... [Read more...]
| Industry Pharmaceutical Preparations | IPO Date Jul 16, 2021 |
| CEO Hugh Y. Rienhoff, Jr., M.D. | Employees 17 |
| Stock Exchange NASDAQ | Ticker Symbol IMGO |